Interferon-α resistance associated genes in renal cell carcinoma identified by expression profiling

被引:5
作者
Korkola, James E.
Kondagunta, G. Varuni
Reuter, Victor E.
Motzer, Robert J.
Chaganti, R. S. K.
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Cell Biol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
关键词
interferon-alpha; gene expression profiling; genes; tumor suppressor; carcinoma; renal cell;
D O I
10.1016/j.juro.2006.11.087
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We identified differentially expressed genes associated with response to pegylated interferon-a treatment in patients with renal cell carcinoma. Materials and Methods: We performed expression profiling on renal cell carcinoma specimens isolated from 23 patients with metastatic disease who were subsequently treated with interferon. Significance Analysis for Microarrays software was used to identify genes that were differentially expressed between patients with partial response compared to those with disease progression. Results: A candidate gene approach looking at VHL and known target genes did not identify any genes whose expression correlated with patient response. A global analysis of approximately 54,000 probe sets identified 4 genes that had expression correlated with response. Reverse transcriptase-polymerise chain reaction analysis of 2 of these genes confirmed that they were more highly expressed in tumors from patients who responded to interferon-a. Interestingly, both of these genes mapped to 4q31-32, a region that has been implicated as the site of a potential tumor suppressor gene in renal cell carcinoma. Conclusions: We have identified 4 genes (3 uncharacterized and 1 known) that may prove useful in predicting response to interferon-a treatment in patients with renal cell carcinoma.
引用
收藏
页码:1264 / 1268
页数:5
相关论文
共 20 条
[1]   Treating cancer with PEG intron - Pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation [J].
Bukowski, RM ;
Tendler, C ;
Cutler, D ;
Rose, E ;
Laughlin, MM ;
Statkevich, P .
CANCER, 2002, 95 (02) :389-396
[2]   Alpha-interferon and its effects on signal transduction pathways [J].
Caraglia, M ;
Marra, M ;
Pelaia, G ;
Maselli, R ;
Caputi, M ;
Marsico, SA ;
Abbruzzese, A .
JOURNAL OF CELLULAR PHYSIOLOGY, 2005, 202 (02) :323-335
[3]   Bioconductor: open software development for computational biology and bioinformatics [J].
Gentleman, RC ;
Carey, VJ ;
Bates, DM ;
Bolstad, B ;
Dettling, M ;
Dudoit, S ;
Ellis, B ;
Gautier, L ;
Ge, YC ;
Gentry, J ;
Hornik, K ;
Hothorn, T ;
Huber, W ;
Iacus, S ;
Irizarry, R ;
Leisch, F ;
Li, C ;
Maechler, M ;
Rossini, AJ ;
Sawitzki, G ;
Smith, C ;
Smyth, G ;
Tierney, L ;
Yang, JYH ;
Zhang, JH .
GENOME BIOLOGY, 2004, 5 (10)
[4]   Targeting tumor cells [J].
Houshmand, P ;
Zlotnik, A .
CURRENT OPINION IN CELL BIOLOGY, 2003, 15 (05) :640-644
[5]  
Jiang F, 2000, CANCER RES, V60, P6503
[6]   Gene expression-based classification of nonseminomatous male germ cell tumors [J].
Korkola, JE ;
Houldsworth, J ;
Dobrzynski, D ;
Olshen, AB ;
Reuter, VE ;
Bosl, GJ ;
Chaganti, RSK .
ONCOGENE, 2005, 24 (32) :5101-5107
[7]   Novel growth and death related interferon-stimulated genes (ISGs) in melanoma:: Greater potency of IFN-β compared with IFN-α2 [J].
Leaman, DW ;
Chawla-Sarkar, M ;
Jacobs, B ;
Vyas, K ;
Sun, YP ;
Ozdemir, A ;
Yi, TL ;
Williams, BR ;
Borden, EC .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2003, 23 (12) :745-756
[8]   Focus on kidney cancer [J].
Linehan, WM ;
Zbar, B .
CANCER CELL, 2004, 6 (03) :223-228
[9]   Identification of novel VHL target genes and relationship to hypoxic response pathways [J].
Maina, EN ;
Morris, MR ;
Zatyka, M ;
Raval, RR ;
Banks, RE ;
Richards, FM ;
Johnson, CM ;
Maher, ER .
ONCOGENE, 2005, 24 (28) :4549-4558
[10]  
Moch H, 1996, CANCER RES, V56, P27